ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "rheumatoid arthritis"

  • Abstract Number: 0232 • ACR Convergence 2024

    Subjective and Objective Measures of Disease Activity in Difficult-to-Treat Rheumatoid Arthritis Patients at Baseline and Follow-up After an Advanced Therapy: An Ultrasound Study

    Seyyid Bilal Acikgoz1, Ricardo Sabido-Sauri2, Ozun Bayindir Tsechelidis3, Ummugulsum Gazel2, Sylvia Sangwa4, Elliot Hepworth2 and Sibel Aydin5, 1University of Ottawa, Rheumatology, Ottawa, ON, Canada, 2University of Ottawa, Ottawa, ON, Canada, 3Ottawa University, Ottawa, ON, Canada, 4The Ottawa Hospital Research Institute, Ottawa, Canada, 5University of Ottawa - Ottawa, Ottawa, ON, Canada

    Background/Purpose: In the era of several advanced therapies and an increasing number of patients with rheumatoid arthritis (RA) who have been failed by multiple therapies,…
  • Abstract Number: 0427 • ACR Convergence 2024

    Association of Menopause and Systemic Rheumatic Disease Severity in Peri-Menopausal and Menopausal Women with Systemic Rheumatic Disease

    Lucy Masto1, Amaya Smole2, Ranqing Lan1, Michael Parides1, Caroline Siegel1, Sarah Lieber1, Jonah Levine1, Bessie Stamm1, Lisa Mandl1, Michael Lockshin3, Lisa Sammaritano4 and Medha Barbhaiya1, 1Hospital for Special Surgery, New York, NY, 2Hospital for Special Surgery, Amherst, MA, 3Hospital for Special Surgery, Weill Cornell Medicine, New York, NY, 4Hospital for Special Surgery, Scarsdale, NY

    Background/Purpose: The relationship between menopause and systemic rheumatic disease (SRD) severity in women with SRDs is poorly understood. Few studies evaluating this association suggest worsening…
  • Abstract Number: 0466 • ACR Convergence 2024

    Inpatient Outcomes of Rheumatoid Arthritis in Hospitalized Patients Using Cannabis: Data from the National Inpatient Sample

    Karun Shrestha1, Prakriti Subedi2, Manoj Ghimire3, Sajana Poudel4, Keerthi Parvathaneni5, Mahmoud Hashim6, Kalpana Ghimire5, Oshna Pandey5, Mohammed Hasan7, Clement Tagoe8 and Liliya Gandrabur9, 1St. Barnabas Hospital Internal Medicine Residency, Bronx, NY, 2St. Barnabas Hospital, Bronx, NY, 3St Barnabas Hospital, BRONX, NY, 4Cook County Health, CHICAGO, NY, 5Department of Internal Medicine, St. Barnabas Hospital, SBH Health System, Bronx, NY 10457, USA, Bronx, NY, 6SBH Health System, New Rochelle, NY, 7Parkview Medical Center, Pueblo, CO, 8Albert Einstein College of Medicine, FRESH MEADOWS, NY, 9SBH Health System, Forest Hills, NY

    Background/Purpose: Despite advancements in rheumatoid arthritis (RA) treatment, effective pain management remains challenging, with many patients also experiencing insomnia, anxiety, and depression. As cannabis legalization…
  • Abstract Number: 0483 • ACR Convergence 2024

    Obesity, Prednisone Use, and Patient-Reported Outcomes Are Predictors of Becoming Difficult-to-Treat in an RA Population Treated with a First-Line Biologic DMARD

    Misti Paudel1, Shravani Chitineni1, Ruogu Li2, Chinmayi Naik3, Nancy Shadick3, Michael Weinblatt4 and Daniel Solomon5, 1Brigham and Women's Hospital, Division of Rheumatology, Inflammation, and Immunity, Boston, MA, 2Brigham and Women's Hospital, Boston, MA, 3Brigham and Women’s Hospital, Boston, MA, 4Brigham and Women's Hospital/ Harvard Medical School, Waban, MA, 5Brigham and Women's Hospital, Newton, MA

    Background/Purpose: Prior studies have evaluated the risk factors for difficult-to-treat RA (D2T-RA) but have not applied EULAR’s full criteria for D2T-RA in a longitudinal data…
  • Abstract Number: 0500 • ACR Convergence 2024

    An Update on the Integrated Safety Analysis of Filgotinib in Patients with Moderate to Severe Active Rheumatoid Arthritis over a Median of 4.3 Years

    Kevin Winthrop1, Daniel Aletaha2, Roberto Caporali3, Yoshiya Tanaka4, Tsutomu Takeuchi5, Vikas Modgill6, Edmund V. Ekoka Omoruyi7, Dick de Vries8, Katrien Van Beneden9, Jacques-Eric Gottenberg10 and Gerd Burmester11, 1School of Medicine, Oregon Health and Science University, Portland, OR, 2Department of Medicine III, Division of Rheumatology, Medical University of Vienna, Wien, Austria, 3Department of Clinical Sciences and Community Health, University of Milan, and Department of Rheumatology and Medical Sciences, ASST Gaetano Pini-CTO, Milan, Italy, 4Department of Internal Medicine, University of Occupational and Environmental Health, Kitakyushu, Fukuoka, Japan, 5Department of Internal Medicine, Keio University, Tokyo, Tokyo, Japan, 6Medical Safety, Galapagos NV, Mechelen, Belgium, 7Biostatistics, Galapagos NV, Mechelen, Belgium, 8Clinical Development, Galapagos BV, Leiden, Netherlands, 9Medical Affairs, Galapagos NV, Mechelen, Belgium, 10Rheumatology Department, Strasbourg University Hospital,, Strasbourg, France, 11Department of Rheumatology and Clinical Immunology, Charité – Universitätsmedizin Berlin, Berlin, Germany

    Background/Purpose: The oral Janus kinase 1-preferential inhibitor filgotinib (FIL) is approved at doses of 100 mg (FIL100) and 200 mg (FIL200) for the treatment of…
  • Abstract Number: 0516 • ACR Convergence 2024

    Management of Elederly Patients with Rheumatoid Arthritis Treated with Tocilizumab : Comparison of Patients over and Under 75 Years Old

    Bruno Fautrel1, Alain SARAUX2, Isabelle Idier3, Henri Bonnabau4, Geoffray Bizouard5 and BERNARD COMBE6, 1INSERM, UMRS 1136, Institut Pierre Louis d'Epidémiologie et de Santé Publique, and Sorbonne University – Assistance Publique-Hôpitaux de Paris, Département de Rhumatologie, Hôpital Pitié-Salpêtrière, Paris, Ile-de-France, France, 2CHU Brest, Brest, France, 3Chugai Pharma france, Puteaux, Ile-de-France, France, 4IQVIA France, Bordeaux, France, 5IQVIA France, La Defense, Ile-de-France, France, 6Montpellier University, LA GRANDE MOTTE, Languedoc-Roussillon, France

    Background/Purpose: Few real-life long-term data are available in RA patients initiating tocilizumab (TCZ) depending on age. The objective of this study was to compare the…
  • Abstract Number: 0534 • ACR Convergence 2024

    Patient Reported Outcomes and Disease Activity from a Phase 1 Double-Blind Randomized Clinical Trial of Allogeneic Mesenchymal Stem Cells in Early Rheumatoid Arthritis

    Alexandre Matar1, Maya Breitman2, Tracey Bonfield3, Maricela Haghiac4, Jane Reese3, Emma Barnboym5, Steven Lewis6, Hillard Lazarus7 and Nora Singer8, 1MetroHealth, Westlake, OH, 2MetroHealth Medical Center,Case Western Reserve University School of Medicine, Cleveland, OH, 3Case Western Reserve University, Cleveland, OH, 4Metrohealth Medical Center, Cleveland, OH, 5The MetroHealth System, Cleveland, OH, 6Case Western University, MetroHealth, Cleveland, OH, 7Case Western Reserve University/University Hospitals, Cleveland, OH, 8MetroHealth System at Case Western Reserve University School of Medicine, Cleveland, OH

    Background/Purpose: Mesenchymal stem (stromal) cells (MSCs) constitute an emerging therapeutic strategy for several human diseases. Small non-randomized studies have shown that MSCs may be a…
  • Abstract Number: 0850 • ACR Convergence 2024

    Assessment of Correlation Between Composite Ultrasonographic Index (ECODAS) and Disease Activity Score 28 in Patients with Rheumatoid Arthritis

    Komal Verma Saluja1, Harshvardhan Khokhar2, Amit Sharma3 and Saurabh Chittora2, 1Government Medical college Kota, Kota, Rajasthan, India, 2Government Medical college Kota, Kota, India, 3Fortis hospital Jaipur, Jaipur, India

    Background/Purpose: Conventional Disease Activity Score 28 has variable sensitivity, subjectivity, inherent bias due to certain variables such as more weightage to joint tenderness and overestimation…
  • Abstract Number: 0906 • ACR Convergence 2024

    Proteomic Signatures of Difficult-to-Treat Rheumatoid Arthritis: Identifying Predictive Biomarkers

    Klára Mocová1, Jiri Baloun1, Aneta Prokopcová2, Kristýna Brábníková Marešová1, Herman Mann3, Jiří Vencovský2, Karel Pavelka4 and Ladislav Šenolt2, 1Institute of Rheumatology, Prague, Czech Republic, 2Institute of Rheumatology and Department of Rheumatology, First Faculty of Medicine, Charles University, Prague, Czech Republic, 3Revmatologický ústav, Praha, Czech Republic, 4Institute of Rheumatology and Charles University, Praha, Czech Republic

    Background/Purpose: Rheumatoid arthritis (RA) is a systemic autoimmune disease characterized by persistent synovial inflammation, progressive joint destruction and extra-articular manifestations. Despite the advancements in the…
  • Abstract Number: 0974 • ACR Convergence 2024

    Number of Days Between Prior Low-dose Weekly Methotrexate Administration and S1-RBD Antibody Response in Adults with Immune Mediated Inflammatory Diseases Vaccinated Against COVID-19: Secondary Analysis of the Vaccine Response On-Off Methotrexate (VROOM) Study Data

    Abhishek Abhishek1, Nicholas Peckham2 and Jonathan Cook2, and the VROOM Study Author Group, 1University of Nottingham, Nottingham, United Kingdom, 2Oxford University, Oxford, United Kingdom

    Background/Purpose: Immunosuppression attenuates immune response to vaccination. A 2-week interruption in low-dose weekly methotrexate immediately after COVID-19 booster improved antibody response to vaccination. There is…
  • Abstract Number: 1023 • ACR Convergence 2024

    Factors Associated with Delays in Dispensation and Insurance Denials of Janus Kinase Inhibitors

    Igor Dombrovsky1, Michael George2, Joshua Baker2 and Thomas Riley3, 1Pennsylvania Hospital, Philadephia, PA, 2University of Pennsylvania, Philadelphia, PA, 3Hopsital of the University of Pennsylvania, Philadelphia, PA

    Background/Purpose: Access to Janus kinase inhibitors (JAKi) is controlled by insurance carriers through prior authorizations and the use of restricted formularies. We previously showed that…
  • Abstract Number: 1130 • ACR Convergence 2024

    Safety of Bispecific T-cell Engager Therapy in Autoimmune Disease

    Melanie Hagen1, Laura Bucci1, Sebastian Boeltz2, Danae-Mona Noethling2, Tobias Rothe2, Maria Gabriella Raimondo1, Carlo Tur1, Andreas Wirsching1, Jochen Wacker1, Aline Bozec1, Georg Schett3 and Ricardo Grieshaber-Bouyer1, 1Department of Medicine 3 - Rheumatology and Immunology, Friedrich-Alexander-Universität (FAU) Erlangen-Nürnberg and Uniklinikum Erlangen, Erlangen, Bayern, Germany, 2Department of Medicine 3 - Rheumatology and Immunology, Friedrich-Alexander-Universität (FAU) Erlangen-Nürnberg and Uniklinikum Erlangen, Erlangen, Germany, 3Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany

    Background/Purpose: B-cells and plasma cells are key drivers of systemic autoimmune diseases (AID). Recent data demonstrated preliminary safety and efficacy of using the CD3xCD19 bispecific…
  • Abstract Number: 1332 • ACR Convergence 2024

    Financial Distress and Its Determinants in Adults with Rheumatoid Arthritis

    Amber Brown Keebler1, Yunju Im2, Sofia Pedro3, Ted Mikuls1, Edward Peters1 and Kaleb Michaud1, 1University of Nebraska Medical Center, Omaha, NE, 2University of Nebraska Medical Center, Omaha, 3Forward, The National Databank for Rheumatic Diseases, Wichita, KS

    Background/Purpose: Often not evaluated in clinical visits, financial distress associated with medical costs, also known as financial toxicity, has emerged as an important factor affecting…
  • Abstract Number: 1348 • ACR Convergence 2024

    Analysis of Body Composition in Patients with Moderate-Severe Rheumatoid Arthritis Treated with Anti-TNF Drugs

    Aimara García-Studer1, Fernando Ortiz-Márquez1, Paula Borregón-Garrido1, Arkaitz Mucientes-Ruiz1, Sara Manrique-Arija1 and Natalia Mena Vázquez2, 1Biomedical Research Institute of Malaga (IBIMA)-Bionand Platform, Department of Rheumatology, Regional University Hospital of Malaga, Malaga, Spain, 2IBIMA, Málaga, Andalucia, Spain

    Background/Purpose: Previous studies have described alterations in fat and lean mass in patients with RA, but the effect of treatments on body composition remains unclear.…
  • Abstract Number: 1364 • ACR Convergence 2024

    Machine Learning-Driven Models for Disease Activity Prediction and Therapeutic Response Evaluation in Rheumatoid Arthritis Patients: An Analysis of Data from the Multicentre, Prospective, Egyptian Collage of Rheumatology (ECR) Study Group

    Nevin Hammam1, Tarek Nahool2, A. M. Yasser3, Eman F Mohamed4, Samar Tharwat5, Doaa Mosad Mosa6, Maha Nassr7, Faten Ismail8, Rawhya R El Shereef8, Nora Y. Elsaid9, Osman Hammam10, Suzan S. Al‑Adle9 and Tamer A Gheita11, 1Rheumatology Department, Faculty of Medicine, Assiut University, Assiut, Egypt, Boston, MA, 2University of the People, Pasadena, CA, USA, Qena, Egypt, 3Physics Department, Faculty of Science, South Valley University, Qena, Egypt; Alchemy Research, Alchemy Global Solutions, Abu Dhabi, UAE, Abu Dhabi, United Arab Emirates, 4Internal Medicine Department, Rheumatology Unit, Faculty of Medicine (Girls), Al-Azhar University, Cairo, Egypt, 5Rheumatology Unit, Internal Medicine, Mansoura University, Dakahlia, 6Rheumatology & Rehabilitation Department, Mansoura University Hospitals, Mansoura University Faculty of Medicine, Egypt, Dakahlia, Egypt, 7Rheumatology Department, Faculty of Medicine, Fayoum University, Fayoum, Egypt, Fayoum, Egypt, 8Rheumatology Department, Faculty of Medicine, Minia University, Minia, Egypt, 9Rheumatology Department, Faculty of Medicine, Cairo University, Cairo, Egypt, Cairo, Egypt, 10Department of Rheumatology and Rehabilitation, Faculty of Medicine, New Valley University, New Valley, Assiut, Egypt, 11Rheumatology Department, Faculty of Medicine, Cairo University, Cairo, Egypt

    Background/Purpose: Rheumatoid arthritis (RA) often exhibits fluctuating and challenging-to-assess clinical courses that lead to irreversible joint destruction. However, a "Treat-to-Target" strategy is recommended aiming to…
  • « Previous Page
  • 1
  • …
  • 45
  • 46
  • 47
  • 48
  • 49
  • …
  • 219
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology